International Assets Investment Management LLC Grows Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

International Assets Investment Management LLC increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 61,995.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,009,671 shares of the medical research company's stock after purchasing an additional 1,008,045 shares during the period. International Assets Investment Management LLC owned approximately 0.26% of Thermo Fisher Scientific worth $535,923,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Boston Trust Walden Corp raised its position in shares of Thermo Fisher Scientific by 1.3% in the fourth quarter. Boston Trust Walden Corp now owns 2,155 shares of the medical research company's stock valued at $1,144,000 after buying an additional 28 shares in the last quarter. Avitas Wealth Management LLC raised its holdings in Thermo Fisher Scientific by 2.9% in the 4th quarter. Avitas Wealth Management LLC now owns 5,050 shares of the medical research company's stock valued at $2,680,000 after acquiring an additional 140 shares in the last quarter. Asset Management One Co. Ltd. grew its holdings in shares of Thermo Fisher Scientific by 4.1% during the 4th quarter. Asset Management One Co. Ltd. now owns 190,876 shares of the medical research company's stock worth $101,722,000 after purchasing an additional 7,595 shares in the last quarter. Quilter Plc increased its position in shares of Thermo Fisher Scientific by 3.9% in the fourth quarter. Quilter Plc now owns 200,681 shares of the medical research company's stock worth $106,604,000 after purchasing an additional 7,540 shares during the period. Finally, DB Fitzpatrick & Co Inc raised its stake in Thermo Fisher Scientific by 17.7% in the fourth quarter. DB Fitzpatrick & Co Inc now owns 3,477 shares of the medical research company's stock valued at $1,846,000 after purchasing an additional 522 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company's stock, valued at $74,039,491.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the firm's stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares of the company's stock, valued at approximately $7,250,362. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the sale, the chief executive officer now owns 123,816 shares of the company's stock, valued at $74,039,491.68. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock worth $28,513,384 in the last quarter. 0.32% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have recently commented on TMO. Raymond James boosted their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an "outperform" rating in a research report on Thursday, February 1st. Citigroup began coverage on Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a "neutral" rating and a $620.00 price target on the stock. TheStreet upgraded Thermo Fisher Scientific from a "c+" rating to a "b-" rating in a research report on Friday, December 22nd. HSBC started coverage on Thermo Fisher Scientific in a research note on Monday, December 18th. They set a "buy" rating and a $610.00 target price for the company. Finally, Barclays lowered shares of Thermo Fisher Scientific from an "overweight" rating to an "equal weight" rating and lifted their price target for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. Five investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average target price of $599.00.

Thermo Fisher Scientific Price Performance

NYSE:TMO traded up $8.85 during trading hours on Friday, hitting $579.46. 1,168,170 shares of the company's stock traded hands, compared to its average volume of 1,234,523. The firm has a market cap of $220.95 billion, a P/E ratio of 37.51, a P/E/G ratio of 2.40 and a beta of 0.80. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The business's fifty day simple moving average is $569.39 and its two-hundred day simple moving average is $523.40. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping analysts' consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. During the same quarter in the prior year, the firm earned $5.40 EPS. The business's revenue for the quarter was down 4.9% compared to the same quarter last year. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Stockholders of record on Friday, March 15th will be given a dividend of $0.39 per share. The ex-dividend date of this dividend is Thursday, March 14th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific's dividend payout ratio is 10.10%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.